Pipeline Therapeutics to Participate in the SVB Leerink 9th Annual Global Healthcare Conference

SAN DIEGO--()--Pipeline Therapeutics, a biopharmaceutical company focused on the development and commercialization of first-in-class small molecules for neuroregeneration, today announced that the company will participate in the SVB Leerink 9th Annual Global Healthcare Conference, taking place February 25-27, 2020, in New York, NY.

About Pipeline Therapeutics

Pipeline Therapeutics is a biopharmaceutical company focused on the development and commercialization of first-in-class small molecules for neuroregeneration, including synaptogenesis, remyelination and axonal repair. The company’s lead product candidate, PIPE-505, is a small molecule gamma secretase inhibitor (GSI) to treat mild-to-moderate sensorineural hearing loss (SNHL) associated with cochlear synaptopathy. The company also has a portfolio of programs, including PIPE-307, focused on remyelination and axonal repair, to address a range of neurological disorders, including multiple sclerosis. For more information, please visit www.pipelinetherapeutics.com.

Contacts

Company Contact:
Carmine Stengone
President and CEO
info@pipelinetherapeutics.com

Investor Contact:
Laurence Watts
619-916-7620
laurence@gilmartinir.com

Release Summary

Pipeline Therapeutics to Participate in the SVB Leerink 9th Annual Global Healthcare Conference

Contacts

Company Contact:
Carmine Stengone
President and CEO
info@pipelinetherapeutics.com

Investor Contact:
Laurence Watts
619-916-7620
laurence@gilmartinir.com